Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Mengqi Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9881-404X; OpenAlex author ID A5100757658. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 3 papers · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  2. O-GlcNAcylation of ZEB1 facilitated mesenchymal pancreatic cancer cell ferroptosis. First author DOI 10.7150/ijbs.71520↗
  3. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  4. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  5. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  6. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  7. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  8. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  9. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  10. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  11. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. First author PMID 31911852↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wensheng Liu · 10 shared papers, 2019–2024 · strength 1.11
  2. Xianjun Yu · 10 shared papers, 2019–2024 · strength 1.11
  3. Shunrong Ji · 10 shared papers, 2019–2024 · strength 1.11
  4. Xiaowu Xu · 9 shared papers, 2019–2021 · strength 0.93
  5. Qiangsheng Hu · 9 shared papers, 2019–2021 · strength 0.93
  6. Wenyan Xu · 8 shared papers, 2019–2024 · strength 0.90
  7. Zheng Zhang · 8 shared papers, 2019–2021 · strength 0.81
  8. Yi Qin · 8 shared papers, 2019–2021 · strength 0.81
  9. Qifeng Zhuo · 6 shared papers, 2020–2024 · strength 0.71
  10. Qiqing Sun · 5 shared papers, 2019–2020 · strength 0.46
  11. Ye Zeng · 4 shared papers, 2020–2021 · strength 0.43
  12. Ye Zeng · 3 shared papers, 2019–2021 · strength 0.31
  13. Wenyan Xu · 2 shared papers, 2019–2021 · strength 0.21
  14. Heli Gao · 1 shared paper, 2024 · strength 0.18
  15. Xinran Liu · 1 shared paper, 2024 · strength 0.18
  16. Zheng Li · 1 shared paper, 2024 · strength 0.18
  17. Haidi Chen · 1 shared paper, 2024 · strength 0.18
  18. Wenjie Tang · 1 shared paper, 2024 · strength 0.18
  19. Chenjie Zhou · 1 shared paper, 2024 · strength 0.18
  20. Xiaowu Xu · 1 shared paper, 2024 · strength 0.18
  21. Aihua Gong · 1 shared paper, 2022 · strength 0.15
  22. Xin Wang · 1 shared paper, 2022 · strength 0.15
  23. Yanfang Liu · 1 shared paper, 2022 · strength 0.15
  24. Haitao Zhu · 1 shared paper, 2022 · strength 0.15
  25. Changfeng Song · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.